Trials / Terminated
TerminatedNCT04853498
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets
A Phase I, Open-label, Dose Escalation and Expansion Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 192 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- Male
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study is conducted to investigate the pharmacokinetic and safety profiles of TQB3720 in patients with metastatic castration-resistant prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB3720 | This is an androgen receptor antagonists. |
Timeline
- Start date
- 2021-06-09
- Primary completion
- 2024-04-30
- Completion
- 2025-12-30
- First posted
- 2021-04-21
- Last updated
- 2026-03-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04853498. Inclusion in this directory is not an endorsement.